Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beau R Webber

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 25, 2015
From marrow to matrix: novel gene and cell therapies for epidermolysis bullosaBeau R Webber, Jakub Tolar
Journal for Immunotherapy of Cancer|December 26, 2025
Genetic engineering and allogeneic optimization of Vδ1 γδ CAR-T cells (ADI-270) for cancer immunotherapyWenlong Liu, Branden S Moriarity, Beau R Webber
Nature Biomedical Engineering|June 11, 2025
A pig with functional human immunityChristopher K Tuggle, Crystal L Loving, Beau R Webber
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 23, 2024
Advancing gene targeting for primary immune deficiencies: Adenine base editing of the human IL2RG locus for correction of SCID-X1R Scott McIvor, Ella J Eaton, Beau R Webber, et al.
Physical Biology|February 17, 2026
Mechanistic modeling predicts efficacy of CISH knockout in tumor-infiltrating lymphocytes with synergistic gene editingNikolaos Memmos, Kamran Kaveh, Beau R Webber, et al.
Biorxiv : the Preprint Server for Biology|September 18, 2025
Mathematical model of CISH knockout predicts increased efficacy in tumor-infiltrating lymphocyte activation with synergistic gene editingNikolaos Memmos, Kamran Kaveh, Beau R Webber, et al.
The Lancet. Oncology|July 31, 2025
CRISPR-engineered T-cell therapies: some clarifications needed - Authors' replyBeau R Webber, Branden S Moriarity, Timothy K Starr, et al.
Scientific Reports|August 16, 2018
Engineering of Primary Human B cells with CRISPR/Cas9 Targeted NucleaseMatthew J Johnson, Kanut Laoharawee, Walker S Lahr, et al.
Frontiers in Immunology|February 2, 2026
Correction: Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risksScott L Baughan, Timothy Folsom, Matt Johnson, et al.
Blood|September 14, 2013
DNA methylation of Runx1 regulatory regions correlates with transition from primitive to definitive hematopoietic potential in vitro and in vivoBeau R Webber, Michelina Iacovino, Si Ho Choi, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 25, 2015
From marrow to matrix: novel gene and cell therapies for epidermolysis bullosaBeau R Webber, Jakub Tolar
Journal for Immunotherapy of Cancer|December 26, 2025
Genetic engineering and allogeneic optimization of Vδ1 γδ CAR-T cells (ADI-270) for cancer immunotherapyWenlong Liu, Branden S Moriarity, Beau R Webber
Nature Biomedical Engineering|June 11, 2025
A pig with functional human immunityChristopher K Tuggle, Crystal L Loving, Beau R Webber
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 23, 2024
Advancing gene targeting for primary immune deficiencies: Adenine base editing of the human IL2RG locus for correction of SCID-X1R Scott McIvor, Ella J Eaton, Beau R Webber, et al.
Physical Biology|February 17, 2026
Mechanistic modeling predicts efficacy of CISH knockout in tumor-infiltrating lymphocytes with synergistic gene editingNikolaos Memmos, Kamran Kaveh, Beau R Webber, et al.
Biorxiv : the Preprint Server for Biology|September 18, 2025
Mathematical model of CISH knockout predicts increased efficacy in tumor-infiltrating lymphocyte activation with synergistic gene editingNikolaos Memmos, Kamran Kaveh, Beau R Webber, et al.
The Lancet. Oncology|July 31, 2025
CRISPR-engineered T-cell therapies: some clarifications needed - Authors' replyBeau R Webber, Branden S Moriarity, Timothy K Starr, et al.
Scientific Reports|August 16, 2018
Engineering of Primary Human B cells with CRISPR/Cas9 Targeted NucleaseMatthew J Johnson, Kanut Laoharawee, Walker S Lahr, et al.
Frontiers in Immunology|February 2, 2026
Correction: Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risksScott L Baughan, Timothy Folsom, Matt Johnson, et al.
Blood|September 14, 2013
DNA methylation of Runx1 regulatory regions correlates with transition from primitive to definitive hematopoietic potential in vitro and in vivoBeau R Webber, Michelina Iacovino, Si Ho Choi, et al.
Pageof 8